EP1272170A1 - Augenwachstum und nikotinische antagonisten - Google Patents

Augenwachstum und nikotinische antagonisten

Info

Publication number
EP1272170A1
EP1272170A1 EP01903112A EP01903112A EP1272170A1 EP 1272170 A1 EP1272170 A1 EP 1272170A1 EP 01903112 A EP01903112 A EP 01903112A EP 01903112 A EP01903112 A EP 01903112A EP 1272170 A1 EP1272170 A1 EP 1272170A1
Authority
EP
European Patent Office
Prior art keywords
nicotinic
eye
nicotinic antagonist
antagonist
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01903112A
Other languages
English (en)
French (fr)
Inventor
Richard A. Stone
Jon M. Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Valley Forge Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valley Forge Pharmaceuticals Inc filed Critical Valley Forge Pharmaceuticals Inc
Publication of EP1272170A1 publication Critical patent/EP1272170A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
EP01903112A 2000-01-18 2001-01-18 Augenwachstum und nikotinische antagonisten Withdrawn EP1272170A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17687500P 2000-01-18 2000-01-18
US176875P 2000-01-18
PCT/US2001/001692 WO2001052832A1 (en) 2000-01-18 2001-01-18 Ocular growth and nicotinic antagonists

Publications (1)

Publication Number Publication Date
EP1272170A1 true EP1272170A1 (de) 2003-01-08

Family

ID=22646232

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01903112A Withdrawn EP1272170A1 (de) 2000-01-18 2001-01-18 Augenwachstum und nikotinische antagonisten

Country Status (10)

Country Link
EP (1) EP1272170A1 (de)
JP (1) JP2003520228A (de)
KR (1) KR20020081260A (de)
CN (1) CN1418095A (de)
AU (1) AU775516B2 (de)
CA (1) CA2400803A1 (de)
HK (1) HK1052464A1 (de)
MX (1) MXPA02007039A (de)
RU (1) RU2002120485A (de)
WO (1) WO2001052832A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080081175A (ko) * 2005-12-19 2008-09-08 코멘티스, 인코포레이티드 안구 투여를 위한 국소 메카밀라민 제형 및 그것의 사용
FI20075498A (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
WO2018164113A1 (ja) 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136686T3 (es) * 1989-06-21 1999-12-01 Univ Pennsylvania Tratamiento y control de desarrollo ocular con agonistas colinergicos.
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0152832A1 *

Also Published As

Publication number Publication date
AU3096901A (en) 2001-07-31
RU2002120485A (ru) 2004-04-10
CA2400803A1 (en) 2001-07-26
WO2001052832A1 (en) 2001-07-26
CN1418095A (zh) 2003-05-14
AU775516B2 (en) 2004-08-05
JP2003520228A (ja) 2003-07-02
HK1052464A1 (zh) 2003-09-19
MXPA02007039A (es) 2003-09-25
KR20020081260A (ko) 2002-10-26

Similar Documents

Publication Publication Date Title
Atkins et al. Region‐specific induction of ΔFosB by repeated administration of typical versus atypical antipsychotic drugs
US20220040126A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
AU2023206175A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
CN101415435A (zh) 用于治疗精神疾病和病症的支链淀粉和支链淀粉激动剂
Gustilo et al. Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons
US20060264508A1 (en) Modulation of ocular growth and myopia by gaba drugs
US20060178307A1 (en) Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
US20030096831A1 (en) Ocular growth and nicotinic antagonists
US8013118B2 (en) Lynx polypeptides
US20080311578A1 (en) System for screening eukaryotic membrane proteins
AU775516B2 (en) Ocular growth and nicotinic antagonists
US20210330646A1 (en) Fascin binding compounds for spinogenesis
US20100168135A1 (en) Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment
Bitzer et al. Effects of muscarinic antagonists on ZENK expression in the chicken retina
KR20230128037A (ko) Er형 미스센스 돌연변이를 갖는 환자에서, c형 니만픽병의 치료를 위한 아리모클로몰
HUE032356T2 (en) New therapeutic methods for treating neurodegenerative conditions
CA2469306A1 (en) Methods and compositions for control of bone formation via modulation of sympathetic tone
KR102124845B1 (ko) 근력증진제로서 stim2 저해제의 용도
IL303969A (en) ugh
US20240050427A1 (en) Treatments for obsessive compulsive disorder
Kieselbach et al. Elevated levels of substance P in intraocular fluid in proliferative vitreoretinopathy
US20050014170A1 (en) Effect of BDNF genotype on hippocampal function and verbal memory and risk for schizophrenia
US20040266677A1 (en) Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof
US20080226653A1 (en) Inhibition of Platelet Aggregation
US20090048146A1 (en) Use of agents that upregulate crystallin expression in the retina and optic nerve head

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

17P Request for examination filed

Effective date: 20020904

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1052464

Country of ref document: HK